GlassScriptPhysician profile
Elizabeth Smith Tryon
NPI 1700864436
$4,446.42
in general payments reported to CMS, 2019-2025
23 companies · $727 in 2025
The $727 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $921 · 2020: $370 · 2021: $634 · 2022: $523 · 2023: $747 · 2024: $524 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,998.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $941.14 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $798.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $700.18 | 2019-2025 | |
| Amgen INC. | $324.30 | 2019-2025 | Prolia, Evenity, Repatha |
| Astellas Pharma US INC | $310.75 | 2019-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $237.13 | 2019-2025 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $218.90 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.25 | 2019-2024 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $107.20 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boston Scientific Corporation | $103.16 | 2020-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.19 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $69.55 | 2022 | |
| Merck Sharp & Dohme LLC | $66.95 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $56.07 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $51.44 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $49.70 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $37.77 | 2024-2025 | Eliquis |
| Exact Sciences Corporation | $33.84 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $30.13 | 2021-2022 | |
| Corcept Therapeutics | $27.94 | 2023-2024 | Korlym |
| Edwards Lifesciences Corporation | $21.93 | 2025 | |
| Esperion Therapeutics, INC. | $18.39 | 2020 | |
| Lundbeck LLC | $14.14 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Smith Tryon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.